Study on the Safety and Effectiveness of Guanxinning Tablets in Intensive Therapy for Patients with Acute Coronary Syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054620

Enrollment

Unknown

Registered

2021-12-21

Start date

2021-12-21

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

Control group:Conventional treatment

Experimental group:The loading treatment group was given intensive treatment with Guanxinning Tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Acute myocardial infarction; 2. Unstable angina.

Exclusion criteria

Exclusion criteria: 1. Aged 180/110mmHg); 6. Pregnant women, lactating women; 7. Allergic constitution, or people with food allergy to various drugs; 8. Patients who have participated in clinical trials of other drugs within 1 month.

Design outcomes

Primary

Measure	Time frame
Antiplatelet aggregation rate;Inflammation-related factors ;Hypersensitive-c-reactive-protein;Nitric Oxide;Oxidative stress indicators ;Troponin T;Creatine kinase isoenzyme;Electrocardiogram;	—

Countries

China

Contacts

Public ContactXu Yizhou

Hangzhou First People's Hospital

qqyzxu@hotmail.com+86 13357109696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026